News
MedPage Today on MSN12h
Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in Second-LineMany patients with ER-positive/HER2-negative advanced breast cancer eventually develop resistance to standard first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback